Showing posts with label genetics. Show all posts
Showing posts with label genetics. Show all posts

GTR: Getting a Handle on Genetic Testing

Genetic tests currently are available for approximately 2,500 diseases. Burgeoning testing capability continues to spawn new products and services. The global market for genetic testing reached US$1.5 billion in 2010 is forecast to reach US$4 billion by 2015, according to RCNOS Industry Research Solutions.

Such rapid growth makes it nearly impossible for researchers, physicians and patients to grasp the scope of genetic testing.

In response, the National Institutes of Health launched the Genetic Testing Registry (GTR) on March 1, 2012. Developed by the National Center for Biotechnology Information, this online resource includes a searchable database of data voluntarily submitted by genetic test providers. Information includes the purpose and limitations of each test, what is measured, methods used and the name and location of the test provider. http://www.ncbi.nlm.nih.gov/gtr

Consumers now have an online resource to explore possibilities and receive referral information for the more than 2,700 certified genetic counselors now practicing in the U.S. 

Medical professionals and researchers can find detailed information about tests' analytic and clinical validity, as well as a their ability to predict or improve outcomes. Peer-reviewed, clinical descriptions of more than 500 conditions and links to a depth of other valuable resources also are available.

NIH Director Francis S. Collins said, "This registry will help a lot of people — from health care professionals looking for answers to their patients' diseases to researchers seeking to identify gaps in scientific knowledge."

The GTR is an important baby step in navigating the new world of genetic testing. We have a long way to go in establishing effective regulation and ethical application.

— Tom DeSanto



A Major Reversal:
No Patents on Genes


Gene patents have been issued for decades. The Patent and Trademark Office has granted thousands of patents on genes from various organisms, including about 20 percent of human genes. This has enabled the biotechnology industry to drive remarkable advances in medicine.

In late October, the Department of Justice declared that human and other genes should not be eligible for patents because they are part of nature.

The road to reversal began when a lawsuit was filed challenging patents covering the BRCA1 and BRCA2 genes and patent-holder Myriad Genetics' screenings that determine predisposition to breast and ovarian cancers. A district court judge in Manhattan ruled the patents invalid because genes carry important information, whether in the body or isolated from it, that can't be patented. His ruling prompted the government to reconsider its policy.

A subsequent friend-of-the-court brief stated: "The chemical structure of native human genes is a product of nature, and it is no less a product of nature when that structure is 'isolated' from its natural environment than are cotton fibers that have been separated from cotton seeds or coal that has been extracted from the earth."

Such a reversal and adamant position could endanger the progress being made in diagnostic testing and in development of highly effective new drugs designed to work in conjunction with the patient's genetic makeup.

I often write about how this progress is already helping patients. BRCA2 screening provided early diagnosis to a cancer victim's children so they could avoid chemotherapy and invasive treatment. In clinical trials, patient-tailored cancer vaccines have brought remission in difficult cases. Extracted genes, and the potential they hold for improving people's lives, are not at all like the limited possibilities of extracted cotton fibers and coal. 

The government's stand on patenting genes is not merely a matter of principle. It's a matter of life and death for current and future patients who depend upon the medical advances made possible through the development and delivery of gene therapies.

Appeals to the government's new stance are in progress. Let's hope they lead to a second reversal and further steps forward for biomedical science and the patients who benefit from it.

— Tom DeSanto

Source: New York Timeds. October 29, 2010. Image: Google Images